Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon
In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...
Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Ozempic Shows Some Promise for Alcohol Use Disorder
The results suggest the potential of semaglutide – the main ingredient in Ozempic and Novo’s higher-dose weight-loss drug ...
The Motley Fool12d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
the two top-selling weight loss drugs. In a 72-week study, Zepbound's mean weight loss was 20.2%, while Wegovy's was 13.7%. Amycretin did better in half the time. Novo Nordisk faces at least two ...
Morningstar9d
Novo Nordisk's Wegovy Drug Sales Miss Expectations
Novo Nordisk's blockbuster Wegovy weight-loss drug just missed sales expectations ... The sales performance comes after Eli Lilly, the company's biggest competitor in the booming weight-loss ...
Novo Nordisk 'comfortable' with impact of Medicare price negotiations for GLP-1s: CEO
Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...
Reuters9d
Novo Nordisk defends next-gen obesity drug CagriSema, details new trial
LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation ... emerges as a strong competitor in the biggest market for obesity drugs, the United States. Novo plans to begin ...